Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by KalVista Pharmaceuticals, Inc. < Previous 1 2 3 4 Next > KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Today 6:30 EDT From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema September 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium August 29, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema August 15, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results July 11, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 June 27, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema June 18, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 June 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 June 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema May 31, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 May 24, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at Upcoming Investor Conferences May 21, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year May 01, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors April 22, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas March 18, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat March 12, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 11, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas March 08, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer March 07, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference March 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 27, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 26, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat February 20, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.